CLINICAL_TRIALS
trial_result
· 2025-02-26
Clinical Trial Update: Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis [Phase 2]
Summary
Phase 2 study evaluating AK120 for moderate-to-severe atopic dermatitis has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Akesobio Australia Pty Ltd | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED